
Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VIGL | US
0.20
6.67%
Healthcare
Biotechnology
30/09/2023
29/11/2023
3.20
3.00
3.30
3.00
Vigil Neuroscience Inc. a clinical-stage biotechnology company focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia the sentinel immune cells of the brain. Its lead candidate is VGL101 a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience Inc. was incorporated in 2020 and is headquartered in Watertown Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
No Dividends (Dividend Yield = 0%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
217.3%1 month
170.6%3 months
157.9%6 months
133.5%0
0
2.12
0.10
0.09
-3.70
0
0
-83.58M
114.81M
114.81M
0
0
0
0
-46.19
16.71
3.75
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
3.99
Range1M
5.70
Range3M
6.36
Rel. volume
0.70
Price X volume
353.36K